A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter, two
parallel-group study in male patients with the AMN phenotype of X-linked adrenoleukodystrophy
(X-ALD) to assess the efficacy and safety of MIN-102 treatment. Study sites will consist of
specialist referral centers experienced in the management of adrenoleukodystrophy (ALD).